In CHL, overexpression of PD-L1 can be a predictive marker for anti-PD-1 therapeutic efficacy [8, 15]; however, harmonization of different IHC assays remains to be accomplished, and interpretations of PD-L1 immunostaining results remain controversial [16, 21, 22]. Here, CD274 is linked to classic Hodgkin lymphoma.